Tapewire

Nasdaq · USD

MRNA

Moderna, Inc.

Export transactions ↓
Tapewire entity
2025
SEC CIK
0001682852
Parsed reports
1,064

Last 12 months

Inside the activity.

0 purchase rows · 19 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202502
Jan 202600
Feb 202601
Mar 202601
Apr 202600
May 202603
Jun 202602
Jul 202601
Aug 202604
Sep 202605
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
May 12, 2021 Filed May 13, 2021 20:10 UTC
Andres JuanSee remarks
Exercise / conversionCommon Stock 5,000 $12.21 $61,050.00
Disclosure

SEC source: 0001127602-21-016548 · form4.xml · nonDerivative · entry 1

Andres Juan · CIK 0001760670 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020.

Read SEC document
May 12, 2021 Filed May 14, 2021 20:06 UTC
Hoge StephenPresident
Exercise / conversionStock Option (Right to Buy) · Derivative 5,000 $0.00 Strike: $10.90 $0.00
Disclosure

SEC source: 0001127602-21-016805 · form4.xml · derivative · entry 8

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 321,972

Underlying: Common Stock · 5,000 shares

Expires 2026-02-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

F3 · derivative.exercise_date: 25% of this option vested and became exercisable on February 23, 2017, with the remainder vesting in 12 equal quarterly installments thereafter.

Read SEC document
May 12, 2021 Filed May 14, 2021 20:06 UTC
Hoge StephenPresident
SaleCommon Stock 5,000 $154.11 $770,550.00
Disclosure

SEC source: 0001127602-21-016805 · form4.xml · nonDerivative · entry 2

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,609,597

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

Read SEC document
May 12, 2021 Filed May 14, 2021 20:06 UTC
Hoge StephenPresident
Exercise / conversionCommon Stock 5,000 $10.90 $54,500.00
Disclosure

SEC source: 0001127602-21-016805 · form4.xml · nonDerivative · entry 1

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,614,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

Read SEC document
May 12, 2021 Filed May 14, 2021 20:11 UTC
Bancel StephaneDirector · Chief Executive Officer
GiftCommon Stock 2,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-016817 · form4.xml · nonDerivative · entry 2

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,312,868

F2 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020, as amended December 23, 2020.

F3 · price: The reported disposition represents a bona fide charitable gift made by the reporting person.

Read SEC document
May 12, 2021 Filed May 14, 2021 20:11 UTC
Bancel StephaneDirector · Chief Executive Officer
SaleCommon Stock 9,000 $154.11 $1,386,990.00
Disclosure

SEC source: 0001127602-21-016817 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,314,868

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on May 21, 2020.

Read SEC document
May 11, 2021 Filed May 13, 2021 20:05 UTC
HENDERSON LORI M.General Counsel and Secretary
Exercise / conversionStock Option (Right to Buy) · Derivative 6,170 $0.00 Strike: $14.85 $0.00
Disclosure

SEC source: 0001127602-21-016541 · form4.xml · derivative · entry 5

HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 361,352

Underlying: Common Stock · 6,170 shares

Expires 2028-06-26

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020.

F3 · derivative.exercise_date: 25% of this option will vest and become exercisable on April 9, 2019 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Read SEC document
May 11, 2021 Filed May 13, 2021 20:05 UTC
HENDERSON LORI M.General Counsel and Secretary
Exercise / conversionStock Option (Right to Buy) · Derivative 430 $0.00 Strike: $20.93 $0.00
Disclosure

SEC source: 0001127602-21-016541 · form4.xml · derivative · entry 4

HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,046

Underlying: Common Stock · 430 shares

Expires 2029-03-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020.

F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Read SEC document
May 11, 2021 Filed May 13, 2021 20:05 UTC
HENDERSON LORI M.General Counsel and Secretary
SaleCommon Stock 6,600 $151.31 $998,646.00
Disclosure

SEC source: 0001127602-21-016541 · form4.xml · nonDerivative · entry 3

HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 901

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020.

Read SEC document
May 11, 2021 Filed May 13, 2021 20:05 UTC
HENDERSON LORI M.General Counsel and Secretary
Exercise / conversionCommon Stock 6,170 $14.85 $91,624.50
Disclosure

SEC source: 0001127602-21-016541 · form4.xml · nonDerivative · entry 2

HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,501

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020.

Read SEC document
May 11, 2021 Filed May 13, 2021 20:05 UTC
HENDERSON LORI M.General Counsel and Secretary
Exercise / conversionCommon Stock 430 $20.93 $8,999.90
Disclosure

SEC source: 0001127602-21-016541 · form4.xml · nonDerivative · entry 1

HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,331

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020.

Read SEC document
May 10, 2021 Filed May 11, 2021 20:12 UTC
Zaks Tal ZviChief Medical Officer
Exercise / conversionStock Option (Right to Buy) · Derivative 3,670 $0.00 Strike: $12.21 $0.00
Disclosure

SEC source: 0001127602-21-016223 · form4.xml · derivative · entry 8

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,612

Underlying: Common Stock · 3,670 shares

Expires 2027-10-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F7 · derivative.exercise_date: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).

Read SEC document
May 10, 2021 Filed May 11, 2021 20:12 UTC
Zaks Tal ZviChief Medical Officer
SaleCommon Stock 200 $163.12 $32,624.00
Disclosure

SEC source: 0001127602-21-016223 · form4.xml · nonDerivative · entry 7

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.00 to $163.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 10, 2021 Filed May 11, 2021 20:12 UTC
Zaks Tal ZviChief Medical Officer
SaleCommon Stock 100 $161.64 $16,164.00
Disclosure

SEC source: 0001127602-21-016223 · form4.xml · nonDerivative · entry 6

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

Read SEC document
May 10, 2021 Filed May 11, 2021 20:12 UTC
Zaks Tal ZviChief Medical Officer
SaleCommon Stock 200 $159.63 $31,926.00
Disclosure

SEC source: 0001127602-21-016223 · form4.xml · nonDerivative · entry 5

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.58 to $159.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 10, 2021 Filed May 11, 2021 20:12 UTC
Zaks Tal ZviChief Medical Officer
SaleCommon Stock 1,585 $158.88 $251,824.80
Disclosure

SEC source: 0001127602-21-016223 · form4.xml · nonDerivative · entry 4

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.28 to $159.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 10, 2021 Filed May 11, 2021 20:12 UTC
Zaks Tal ZviChief Medical Officer
SaleCommon Stock 985 $157.48 $155,117.80
Disclosure

SEC source: 0001127602-21-016223 · form4.xml · nonDerivative · entry 3

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,085

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.03 to $158.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 10, 2021 Filed May 11, 2021 20:12 UTC
Zaks Tal ZviChief Medical Officer
SaleCommon Stock 600 $156.60 $93,960.00
Disclosure

SEC source: 0001127602-21-016223 · form4.xml · nonDerivative · entry 2

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,070

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.99 to $156.87. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 10, 2021 Filed May 11, 2021 20:12 UTC
Zaks Tal ZviChief Medical Officer
Exercise / conversionCommon Stock 3,670 $12.21 $44,810.70
Disclosure

SEC source: 0001127602-21-016223 · form4.xml · nonDerivative · entry 1

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,670

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

Read SEC document
May 10, 2021 Filed May 11, 2021 20:10 UTC
Andres JuanSee remarks
Exercise / conversionStock Option (Right to Buy) · Derivative 5,000 $0.00 Strike: $12.21 $0.00
Disclosure

SEC source: 0001127602-21-016220 · form4.xml · derivative · entry 3

Andres Juan · CIK 0001760670 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 539,822

Underlying: Common Stock · 5,000 shares

Expires 2027-08-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020.

F2 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

Read SEC document
May 10, 2021 Filed May 11, 2021 20:10 UTC
Andres JuanSee remarks
SaleCommon Stock 5,000 $164.38 $821,900.00
Disclosure

SEC source: 0001127602-21-016220 · form4.xml · nonDerivative · entry 2

Andres Juan · CIK 0001760670 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020.

Read SEC document
May 10, 2021 Filed May 11, 2021 20:10 UTC
Andres JuanSee remarks
Exercise / conversionCommon Stock 5,000 $12.21 $61,050.00
Disclosure

SEC source: 0001127602-21-016220 · form4.xml · nonDerivative · entry 1

Andres Juan · CIK 0001760670 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020.

Read SEC document
May 07, 2021 Filed May 11, 2021 20:08 UTC
Bancel StephaneDirector · Chief Executive Officer
SaleCommon Stock 533 $168.48 $89,799.84
Disclosure

SEC source: 0001127602-21-016218 · form4.xml · nonDerivative · entry 7

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 33,154

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $168.04 to $168.99. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

Read SEC document
May 07, 2021 Filed May 11, 2021 20:08 UTC
Bancel StephaneDirector · Chief Executive Officer
SaleCommon Stock 600 $166.83 $100,098.00
Disclosure

SEC source: 0001127602-21-016218 · form4.xml · nonDerivative · entry 6

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 33,687

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $166.54 to $167.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

Read SEC document
May 07, 2021 Filed May 11, 2021 20:08 UTC
Bancel StephaneDirector · Chief Executive Officer
SaleCommon Stock 781 $165.76 $129,458.56
Disclosure

SEC source: 0001127602-21-016218 · form4.xml · nonDerivative · entry 5

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 34,287

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $165.29 to $165.98. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

Read SEC document
May 07, 2021 Filed May 11, 2021 20:08 UTC
Bancel StephaneDirector · Chief Executive Officer
SaleCommon Stock 788 $164.64 $129,736.32
Disclosure

SEC source: 0001127602-21-016218 · form4.xml · nonDerivative · entry 4

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 35,068

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $164.13 to $165.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

Read SEC document
May 07, 2021 Filed May 11, 2021 20:08 UTC
Bancel StephaneDirector · Chief Executive Officer
SaleCommon Stock 4,149 $163.54 $678,527.46
Disclosure

SEC source: 0001127602-21-016218 · form4.xml · nonDerivative · entry 3

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 35,856

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.09 to $164.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

Read SEC document
May 07, 2021 Filed May 11, 2021 20:08 UTC
Bancel StephaneDirector · Chief Executive Officer
SaleCommon Stock 3,595 $162.81 $585,301.95
Disclosure

SEC source: 0001127602-21-016218 · form4.xml · nonDerivative · entry 2

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 40,005

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.08 to $163.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

Read SEC document
May 07, 2021 Filed May 11, 2021 20:08 UTC
Bancel StephaneDirector · Chief Executive Officer
SaleCommon Stock 600 $161.18 $96,708.00
Disclosure

SEC source: 0001127602-21-016218 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 43,600

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $160.94 to $161.39. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

Read SEC document
May 06, 2021 Filed May 7, 2021 20:09 UTC
HENDERSON LORI M.General Counsel and Secretary
Exercise / conversionStock Option (Right to Buy) · Derivative 6,600 $0.00 Strike: $20.93 $0.00
Disclosure

SEC source: 0001127602-21-015855 · form4.xml · derivative · entry 3

HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 93,476

Underlying: Common Stock · 6,600 shares

Expires 2029-03-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020.

F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Read SEC document
May 06, 2021 Filed May 7, 2021 20:09 UTC
HENDERSON LORI M.General Counsel and Secretary
SaleCommon Stock 6,600 $147.82 $975,612.00
Disclosure

SEC source: 0001127602-21-015855 · form4.xml · nonDerivative · entry 2

HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 901

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020.

Read SEC document
May 06, 2021 Filed May 7, 2021 20:09 UTC
HENDERSON LORI M.General Counsel and Secretary
Exercise / conversionCommon Stock 6,600 $20.93 $138,138.00
Disclosure

SEC source: 0001127602-21-015855 · form4.xml · nonDerivative · entry 1

HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,501

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020.

Read SEC document
May 06, 2021 Filed May 7, 2021 20:05 UTC
Bancel StephaneDirector · Chief Executive Officer
SaleCommon Stock 10,000 $147.82 $1,478,200.00
Disclosure

SEC source: 0001127602-21-015847 · form4.xml · nonDerivative · entry 3

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 7,424,880

F4 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019.

F5 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

Read SEC document
May 05, 2021 Filed May 6, 2021 20:06 UTC
Andres JuanSee remarks
Exercise / conversionStock Option (Right to Buy) · Derivative 5,000 $0.00 Strike: $12.21 $0.00
Disclosure

SEC source: 0001127602-21-015713 · form4.xml · derivative · entry 3

Andres Juan · CIK 0001760670 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 544,822

Underlying: Common Stock · 5,000 shares

Expires 2027-08-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020.

F2 · derivative.exercise_date: 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

Read SEC document
May 05, 2021 Filed May 6, 2021 20:06 UTC
Andres JuanSee remarks
SaleCommon Stock 5,000 $178.34 $891,700.00
Disclosure

SEC source: 0001127602-21-015713 · form4.xml · nonDerivative · entry 2

Andres Juan · CIK 0001760670 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020.

Read SEC document
May 05, 2021 Filed May 6, 2021 20:06 UTC
Andres JuanSee remarks
Exercise / conversionCommon Stock 5,000 $12.21 $61,050.00
Disclosure

SEC source: 0001127602-21-015713 · form4.xml · nonDerivative · entry 1

Andres Juan · CIK 0001760670 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, as amended on December 23, 2020.

Read SEC document
May 05, 2021 Filed May 7, 2021 20:05 UTC
Bancel StephaneDirector · Chief Executive Officer
GiftCommon Stock 2,000 Not disclosed Not disclosed
Disclosure

SEC source: 0001127602-21-015847 · form4.xml · nonDerivative · entry 2

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,323,868

F2 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020, as amended December 23, 2020.

F3 · price: The reported disposition represents a bona fide charitable gift made by the reporting person.

Read SEC document
May 05, 2021 Filed May 7, 2021 20:05 UTC
Bancel StephaneDirector · Chief Executive Officer
SaleCommon Stock 9,000 $178.34 $1,605,060.00
Disclosure

SEC source: 0001127602-21-015847 · form4.xml · nonDerivative · entry 1

Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,325,868

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020.

Read SEC document
May 04, 2021 Filed May 6, 2021 20:08 UTC
HENDERSON LORI M.General Counsel and Secretary
Exercise / conversionStock Option (Right to Buy) · Derivative 6,600 $0.00 Strike: $20.93 $0.00
Disclosure

SEC source: 0001127602-21-015715 · form4.xml · derivative · entry 3

HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,076

Underlying: Common Stock · 6,600 shares

Expires 2029-03-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020.

F2 · derivative.exercise_date: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Read SEC document
May 04, 2021 Filed May 6, 2021 20:08 UTC
HENDERSON LORI M.General Counsel and Secretary
SaleCommon Stock 6,600 $185.25 $1,222,650.00
Disclosure

SEC source: 0001127602-21-015715 · form4.xml · nonDerivative · entry 2

HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 901

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020.

Read SEC document
May 04, 2021 Filed May 6, 2021 20:08 UTC
HENDERSON LORI M.General Counsel and Secretary
Exercise / conversionCommon Stock 6,600 $20.93 $138,138.00
Disclosure

SEC source: 0001127602-21-015715 · form4.xml · nonDerivative · entry 1

HENDERSON LORI M. · CIK 0001221127 · General Counsel and Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,501

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2020.

Read SEC document
May 03, 2021 Filed May 4, 2021 20:52 UTC
Hoge StephenPresident
Exercise / conversionStock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $0.99 $0.00
Disclosure

SEC source: 0001127602-21-015241 · form4.xml · derivative · entry 7

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 497,431

Underlying: Common Stock · 10,000 shares

Expires 2023-08-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

F3 · derivative.exercise_date: This option is fully vested and exercisable.

Read SEC document
May 03, 2021 Filed May 4, 2021 20:52 UTC
Hoge StephenPresident
Exercise / conversionStock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $0.99 $0.00
Disclosure

SEC source: 0001127602-21-015241 · form4.xml · derivative · entry 6

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 507,431

Underlying: Common Stock · 10,000 shares

Expires 2023-08-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

F3 · derivative.exercise_date: This option is fully vested and exercisable.

Read SEC document
May 03, 2021 Filed May 4, 2021 20:52 UTC
Hoge StephenPresident
SaleCommon Stock 20,000 $183.66 $3,673,200.00
Disclosure

SEC source: 0001127602-21-015241 · form4.xml · nonDerivative · entry 3

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,609,597

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

Read SEC document
May 03, 2021 Filed May 4, 2021 20:52 UTC
Hoge StephenPresident
Exercise / conversionCommon Stock 10,000 $0.99 $9,900.00
Disclosure

SEC source: 0001127602-21-015241 · form4.xml · nonDerivative · entry 2

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,629,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

Read SEC document
May 03, 2021 Filed May 4, 2021 20:52 UTC
Hoge StephenPresident
Exercise / conversionCommon Stock 10,000 $0.99 $9,900.00
Disclosure

SEC source: 0001127602-21-015241 · form4.xml · nonDerivative · entry 1

Hoge Stephen · CIK 0001760669 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,619,597

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on January 7, 2021.

Read SEC document
May 03, 2021 Filed May 4, 2021 20:56 UTC
Zaks Tal ZviChief Medical Officer
Exercise / conversionStock Option (Right to Buy) · Derivative 5,000 $0.00 Strike: $12.21 $0.00
Disclosure

SEC source: 0001127602-21-015257 · form4.xml · derivative · entry 7

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,282

Underlying: Common Stock · 5,000 shares

Expires 2027-10-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F7 · derivative.exercise_date: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).

Read SEC document
May 03, 2021 Filed May 4, 2021 20:56 UTC
Zaks Tal ZviChief Medical Officer
SaleCommon Stock 916 $188.00 $172,208.00
Disclosure

SEC source: 0001127602-21-015257 · form4.xml · nonDerivative · entry 6

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $187.69 to $188.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 03, 2021 Filed May 4, 2021 20:56 UTC
Zaks Tal ZviChief Medical Officer
SaleCommon Stock 1,924 $187.10 $359,980.40
Disclosure

SEC source: 0001127602-21-015257 · form4.xml · nonDerivative · entry 5

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 916

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $186.65 to $187.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 03, 2021 Filed May 4, 2021 20:56 UTC
Zaks Tal ZviChief Medical Officer
SaleCommon Stock 1,089 $186.04 $202,597.56
Disclosure

SEC source: 0001127602-21-015257 · form4.xml · nonDerivative · entry 4

Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,840

F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $185.54 to $186.54 Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.